Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

The US$498 analyst price target for VRTX is 38% less than our estimate of fair value Does the April share price for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reflect what it's really worth?

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

On Wednesday, CrowdStrike announced an expansion of its partnership with Alphabet Inc 's GOOG +0.73% Get Free Report Google Cloud to enable end-to-end security for AI innovation with the company's ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

The stock's rise snapped a three-day losing streak.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...